# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experienc...
IMUNON, Inc. (NASDAQ:IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on de...
- SEC Filing
HC Wainwright & Co. analyst Emily Bodnar maintains Imunon (NASDAQ:IMNN) with a Buy and raises the price target from $12 ...